Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Dianthus Therapeutics Inc.

Healthcare US DNTH

82.07USD
5.62(7.35%)

Last update at 2026-06-12T20:00:00Z

Day Range

77.1683.61
LowHigh

52 Week Range

16.6496.50
LowHigh

Fundamentals

  • Previous Close 76.45
  • Market Cap4908.56M
  • Volume1380718
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-177.82200M
  • Revenue TTM2.04M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 2.04M
  • Diluted EPS TTM-4.2

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -162.33700M -84.96900M -43.55500M -28.47600M -13.10900M
Minority interest - - - - -
Net income -162.33700M -84.96900M -43.55500M -28.47600M -13.10900M
Selling general administrative 34.33M 24.99M 18.16M 6.74M 1.96M
Selling and marketing expenses - - 0.35M - -
Gross profit 2.04M 6.24M 2.83M 6.42M 1.48M
Reconciled depreciation 0.43M 0.41M 0.30M 0.15M 0.00000M
Ebit - -101.86400M -48.17400M -29.84100M -15.08000M
Ebitda -177.93300M -101.45200M -47.81900M -29.69400M -13.06000M
Depreciation and amortization - 0.41M 0.35M 0.15M 2.02M
Non operating income net other - - - - -
Operating income -177.93300M -101.86400M -48.17400M -29.70500M -13.08600M
Other operating expenses 179.97M 108.10M 51.00M 36.12M 14.56M
Interest expense - - - - 3.56M
Tax provision - - - - -
Interest income 16.12M 17.36M 2.96M 1.15M 0.00300M
Net interest income 16.12M 17.36M 2.96M 1.15M 0.00300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.19M -1.28100M -1.99700M
Total revenue 2.04M 6.24M 2.83M 6.42M 1.48M
Total operating expenses 179.97M 108.10M 51.00M 36.12M 14.56M
Cost of revenue - 0.41M 0.35M - -
Total other income expense net 15.60M 16.89M 4.62M 0.08M -0.02600M
Discontinued operations - - - - -
Net income from continuing ops -162.33700M -84.96900M -43.10800M -28.47600M -13.10900M
Net income applicable to common shares - - - -28.47600M -13.10900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 530.92M 374.01M 179.41M 83.11M 9.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.04M 4.86M 3.25M 0.05M 0.01000M
Total liab 37.52M 21.53M 10.54M 127.48M 26.70M
Total stockholder equity 493.40M 352.48M 168.87M -44.36800M -17.24900M
Deferred long term liab - - - - -
Other current liab 19.45M 13.07M 6.50M 6.61M 3.99M
Common stock 0.04M 0.03M 0.01M 0.06M 0.06M
Capital stock 0.04M 0.03M 0.01M 0.00000M 0.00000M
Retained earnings -336.72900M -174.39200M -89.42300M -45.86800M -17.39200M
Other liab - - - 0.79M -
Good will - - - - -
Other assets - - - 0.12M 0.03M
Cash 51.09M 22.79M 132.32M 15.37M 7.64M
Cash and equivalents - - - - -
Total current liabilities 30.73M 18.45M 9.63M 8.22M 5.35M
Current deferred revenue 1.19M 0.48M 0.10M 0.10M -
Net debt -49.70100M -21.30100M -131.74000M -14.57700M -7.63800M
Short term debt 0.37M 0.32M 0.42M 0.35M -
Short long term debt - - - - -
Short long term debt total 1.39M 1.49M 0.58M 0.79M -
Other stockholder equity 829.60M 526.73M 78.83M 1.60M 0.11M
Property plant equipment - - - 0.96M 0.03M
Total current assets 409.44M 280.90M 177.45M 82.03M 9.39M
Long term investments 110.14M 81.73M - - -
Net tangible assets - - - -44.36800M -17.24900M
Short term investments 353.21M 252.45M 41.39M 60.12M 45.28M
Net receivables 0.10M 0.81M 0.48M 5.64M 1.48M
Long term debt - - - - -
Inventory - - - 0.85M 0.26M
Accounts payable 9.72M 4.58M 2.61M 1.17M 1.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.49M 0.11M 0.05M -0.16100M -0.03000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 9.72M 9.63M 1.09M 0.12M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 121.48M 93.10M 1.95M 1.08M 0.06M
Capital lease obligations 1.39M 1.49M 0.58M 0.79M 0.00000M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -122.62000M -286.81200M 15.82M -59.81900M -0.03300M
Change to liabilities - - - 3.17M 4.92M
Total cashflows from investing activities -122.83300M -286.81200M 20.25M -59.81900M -0.03300M
Net borrowings - 0.00000M 0.00000M - -
Total cash from financing activities 280.12M 255.62M 133.57M 96.68M 14.91M
Change to operating activities - - - -4.89300M -0.77000M
Net income -162.33700M -84.96900M -43.55500M -28.47600M -13.10900M
Change in cash 28.23M -109.36900M 116.97M 7.79M 4.97M
Begin period cash flow 23.02M 132.39M 15.43M 7.64M 2.66M
End period cash flow 51.25M 23.02M 132.39M 15.43M 7.64M
Total cash from operating activities -129.06000M -78.18000M -36.86100M -29.07000M -9.90400M
Issuance of capital stock 272.27M 269.20M 72.00M 100.00M 15.00M
Depreciation 0.43M 0.41M 0.35M 0.15M 2.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.76M 0.00000M 5.16M 0.07M -1.00700M
Sale purchase of stock 0.32M - - - -
Other cashflows from financing activities 280.12M -13.57500M 61.57M 93.77M 14.91M
Change to netincome - - - 0.91M 0.06M
Capital expenditures 0.21M 0.10M 0.11M 0.14M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 16.73M -0.35100M 4.86M -1.65300M 3.14M
Stock based compensation 22.79M 12.89M 2.90M 1.52M 0.06M
Other non cash items -6.67000M -6.16600M -0.76200M -0.60600M -2.02000M
Free cash flow -129.27300M -78.28500M -36.97100M -29.20900M -9.93700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DNTH
Dianthus Therapeutics Inc.		 5.62 7.35% 82.07 - - 2410.88 9.95 2212.99 -7.3451
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics Inc.

7 Times Square, New York, NY, United States, 10036

Key Executives

Name Title Year Born
Mr. Marino Garcia M.B.A. President, CEO, Secretary & Director 1966
Mr. Ryan Savitz CFO and Chief Business Officer & Treasurer NA
Mr. Edward G. Carr Chief Accounting Officer 1969
Mr. Judson Taylor Head of Technical Operations NA
Dr. Jeffrey Stavenhagen Ph.D. Chief Scientific Officer NA
Ms. Jennifer Davis Ruff VP and Head of Investor Relations & Corporate Affairs. NA
Mr. Adam M. Veness Esq. General Counsel 1986
Ms. Kristina Maximenko Chief People Officer NA
Mr. Simrat Randhawa M.B.A., M.D. Chief Medical Officer NA
Ms. Rashieda Gluck Head of Clinical Development Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.